Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder

Peter Hauser, Benjamin Morasco, Alex Linke, Dannell Bjornson, Samantha Ruimy, Annette Matthews, Aly Rifai, David W. Indest, Jennifer Loftis

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. Objective: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD). Method: The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. Results: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. Conclusion: Patients with MDD can be safely and effectively treated with antiviral therapy.

Original languageEnglish (US)
Pages (from-to)500-505
Number of pages6
JournalPsychosomatics
Volume50
Issue number5
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Major Depressive Disorder
Hepatitis C
Hepacivirus
Antiviral Agents
Informed Consent
Substance-Related Disorders
Psychiatry
Comorbidity
Therapeutics
Completion
Virus
Education
Sustained Virologic Response
Therapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Applied Psychology

Cite this

Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. / Hauser, Peter; Morasco, Benjamin; Linke, Alex; Bjornson, Dannell; Ruimy, Samantha; Matthews, Annette; Rifai, Aly; Indest, David W.; Loftis, Jennifer.

In: Psychosomatics, Vol. 50, No. 5, 09.2009, p. 500-505.

Research output: Contribution to journalArticle

Hauser, Peter ; Morasco, Benjamin ; Linke, Alex ; Bjornson, Dannell ; Ruimy, Samantha ; Matthews, Annette ; Rifai, Aly ; Indest, David W. ; Loftis, Jennifer. / Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. In: Psychosomatics. 2009 ; Vol. 50, No. 5. pp. 500-505.
@article{9b7e8866820543f29299e75c63a8684b,
title = "Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder",
abstract = "Background: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. Objective: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD). Method: The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. Results: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. Conclusion: Patients with MDD can be safely and effectively treated with antiviral therapy.",
author = "Peter Hauser and Benjamin Morasco and Alex Linke and Dannell Bjornson and Samantha Ruimy and Annette Matthews and Aly Rifai and Indest, {David W.} and Jennifer Loftis",
year = "2009",
month = "9",
doi = "10.1176/appi.psy.50.5.500",
language = "English (US)",
volume = "50",
pages = "500--505",
journal = "Psychosomatics",
issn = "0033-3182",
publisher = "American Psychiatric Publishing Inc.",
number = "5",

}

TY - JOUR

T1 - Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder

AU - Hauser, Peter

AU - Morasco, Benjamin

AU - Linke, Alex

AU - Bjornson, Dannell

AU - Ruimy, Samantha

AU - Matthews, Annette

AU - Rifai, Aly

AU - Indest, David W.

AU - Loftis, Jennifer

PY - 2009/9

Y1 - 2009/9

N2 - Background: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. Objective: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD). Method: The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. Results: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. Conclusion: Patients with MDD can be safely and effectively treated with antiviral therapy.

AB - Background: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. Objective: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD). Method: The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. Results: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. Conclusion: Patients with MDD can be safely and effectively treated with antiviral therapy.

UR - http://www.scopus.com/inward/record.url?scp=73249134531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73249134531&partnerID=8YFLogxK

U2 - 10.1176/appi.psy.50.5.500

DO - 10.1176/appi.psy.50.5.500

M3 - Article

C2 - 19855036

AN - SCOPUS:73249134531

VL - 50

SP - 500

EP - 505

JO - Psychosomatics

JF - Psychosomatics

SN - 0033-3182

IS - 5

ER -